CompletedPhase 3NCT00288704
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Studying Autoinflammatory syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Robert Evans, PharmD.Regeneron Pharmaceuticals
- Intervention
- rilonacept 160 mg(drug)
- Enrollment
- 104 enrolled
- Eligibility
- 7 years · All sexes
- Timeline
- 2005 – 2008
Study locations (24)
- Little Rock, Arkansas, United States
- Palm Desert, California, United States
- Upland, California, United States
- Jacksonville, Florida, United States
- Stuart, Florida, United States
- Atlanta, Georgia, United States
- Columbus, Georgia, United States
- Aurora, Illinois, United States
- Louisville, Kentucky, United States
- Shreveport, Louisiana, United States
- Chesterfield, Michigan, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Raleigh, North Carolina, United States
- Cincinnati, Ohio, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00288704 on ClinicalTrials.govOther trials for Autoinflammatory syndrome
Additional recruiting or active studies for the same condition.